Literature DB >> 30955978

Acquisition of specific antibodies and their influence on cell-mediated immune response in neonatal cord blood after maternal pertussis vaccination during pregnancy.

Laila Lima1, Mariela da Gama Fortunato Molina2, Beatriz Sena Pereira3, Marvin Lucas Ale Nadaf2, Maria Isabel Valdomir Nadaf2, Olga Akiko Takano2, Magda Carneiro-Sampaio3, Patricia Palmeira4.   

Abstract

Maternal immunization with pertussis acellular vaccine (Tdap) is an intervention that provides protection to newborns. However, it has been reported that high maternal antibody levels may adversely affect the immune response of infants after active immunization. In this study, we evaluated neonatal passive acquisition of pertussis-specific antibodies and their influence on the neonatal cell-mediated immune response. Pregnant women were either vaccinated with Tdap vaccine (case group, n = 66) or received no vaccine (control group, n = 101). Whole-cell Bordetella pertussis (Bp), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)-specific serum IgG were quantified in paired maternal-cord sera, and Bp- and PT-specific IgA were evaluated in colostrum by ELISA. Ex vivo neonatal blood lymphocyte responsiveness after Bp stimulation was assessed in case (n = 17) and control (n = 15) groups using flow cytometry to detect proliferation, cytokine production and activation phenotype of lymphocytes in the context of high specific IgG acquired after maternal vaccination. Anti-Bp, PT, FHA and PRN IgG concentrations in maternal and cord sera from case group were higher than those in control group with positive correlation indexes in both groups for all pertussis antigens. The control group presented higher placental transfer ratios of specific antibodies and, in the case group, vaccination between 26 and 31 gestation weeks was associated with the best placental transfer ratios. Specific IgA concentrations in colostrum were not affected by vaccine status. Whole blood assays revealed that newborns responded to Bp stimulation with higher expression of CD40L, CD69 and CD4+ T cell proliferation compared to unstimulated cells, and a lower Th1 response, while a preserved Th2 response compared to adults, but there were no differences between the neonatal groups for any of the studied parameters. Our results indicate that higher pertussis-specific IgG levels in newborn sera after maternal vaccination do not affect the neonatal ex vivo cell-mediated immune response.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bordetella pertussis; IgG placental transfer; Neonatal T-cell response; Tdap vaccine in pregnancy

Year:  2019        PMID: 30955978     DOI: 10.1016/j.vaccine.2019.03.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status.

Authors:  Annalisa L Post; Shuk Hang Li; Madison Berry; Hannah Itell; David R Martinez; Guanhua Xie; Sallie R Permar; Geeta K Swamy; Genevieve G Fouda
Journal:  Vaccine       Date:  2020-05-29       Impact factor: 3.641

Review 2.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Authors:  Anja Saso; Beate Kampmann; Sophie Roetynck
Journal:  Vaccines (Basel)       Date:  2021-08-07

Review 3.  Maternal vaccination as an additional approach to improve the protection of the nursling: Anti-infective properties of breast milk.

Authors:  Yingying Zheng; Simone Correa-Silva; Patricia Palmeira; Magda Carneiro-Sampaio
Journal:  Clinics (Sao Paulo)       Date:  2022-08-10       Impact factor: 2.898

4.  CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk.

Authors:  Valdenise Martins Laurindo Tuma Calil; Patricia Palmeira; Yingying Zheng; Vera Lúcia Jornada Krebs; Werther Brunow de Carvalho; Magda Carneiro-Sampaio
Journal:  Clinics (Sao Paulo)       Date:  2021-06-28       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.